Hopp til innhold
NHI.no
Annonse

Denguefeber: Prognose

Innhold i artikkelen

Prognosen er god hos tidligere friske personer. Denguefeber er vanligvis selvbegrensende og har en dødelighet under 1 prosent. Sykdom medfører livsvarig immunitet for den aktuelle serotype (type 1-4), men ingen kryssimmunitet.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Denguefeber . Referanselisten for dette dokumentet vises nedenfor

  1. World Health Organization, Regional Office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever - revised and expanded edition. 2011. http://www.searo.who.int/ (last accessed 29 June 2015).
  2. Centers for Disease Control and Prevention. Dengue. For health care providers. July 14, 2020. www.cdc.gov
  3. Smittevernveilederen. Denguefeber - veileder for helsepersonell. Folkehelseinstituttet, siste oppdatering 08.08.2019. fhi.no
  4. European Centre for Disease Prevention and Control. Dengue worldwide overview. 20.December 2019. www.ecdc.europa.eu
  5. WHO. Dengue and severe dengue. 23 June 2020. www.who.int
  6. Simmons CP, Farrar JJ, Nguyen VV, et al. Dengue. N Engl J Med. 2012;366:1423-1432. PubMed
  7. Blystad H, Borgen K. Dødelig denguevirus-infeksjon etter turistopphold i Thailand. MSIS 2008; 36: 9. PubMed
  8. Thomas SJ, Rothman AL, Srikiatkhachorn A, Kalayanarooj S. Dengue virus infection: Prevention and treatment. UpToDate, last updated Sep 11, 2018. UpToDate
  9. Guzman MG, Kouri G. Dengue and dengue haemorrhagic fever in America: lessons and challenges. J Clin Virol. 2007;27:1-13. PubMed
  10. Gregory CJ, Santiago LM, Argüello LM, et al. Clinical and laboratory features that differentiate dengue from other febrile illnesses en an endemic area--Puerto Rico, 2007-2008. Am J Trop Med Hyg 2010; 82: 922-9. PubMed
  11. Lindegren G, Vene S, Lundkvist Å, Falk KI. Optimized diagnosis of acute dengue fever in Swedish travelers by a combination of reverse transcription-PCR and immunoglobin M detection. J Clin Microbiol 2005; 43: 2850-5. PubMed
  12. World Mosquito Program. Wolbachia. Siden besøkt 10.01.2020. www.eliminatedengue.com
  13. Nature. News. The mosquito strategy that could eliminate dengue. Callaway E, publisert 27.8.2020. www.nature.com
  14. Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med 2019; 381:2009-2019. www.nejm.org
  15. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalnet dengue vaccine in helathy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014. doi:10.1016/S0140-6736(14)61060-6 DOI
  16. Olivera-Botello G et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis 2016 Oct 1; 214:994
  17. Evaluation of the Performance of a Dengue IgG Rapid Diagnostic Test for the Determination of Dengue Serostatus as Part of Pre-Vaccination Screening. Session: Parallel Symposium 13: Controlling Arthropod Tropical Infections ntk-institute.org
  18. Nilsson J, Vene S, Mattsson L. Dengue encephalitis in a Swedish traveller returning from Thailand. Scand J Infect Dis 2005; 776-8.
  19. Blacksell SD, Newton PN, Bell D, Kelley J, Mammen MP, Vaughn DW et al. The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection. Clin Infect Dis 2006; 42: 1127-34. PubMed
Annonse
Annonse